Genzyme Corp. (NASDAQ:GENZ) CEO Henri Termeer has cut his stake in Danvers, Massachusetts-based Abiomed Inc. (NASDAQ:ABMD) by about 5.4 percent over the past year.
Between November 2009 and Nov. 9 of this year, Termeer, an Abiomed board member, shed nearly 277,000 shares of the company’s stock, for an average price of $10.25, netting $2.7 million, according to Securities & Exchange Commission filings. ABMD shares traded at an average of $9.71 during that span.
Termeer’s latest trades of 5,000 and 10,000 shares on Nov. 9 and Nov. 10 were made at share prices of $11.85 and $12.02 per share, respectively, netting him $179,450, according to a filing.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The latest sales began five days after the cardiac assist device maker reported earnings for a fiscal quarter that Abiomed CEO Michael Minogue called the company’s “best quarter in our 29-year history.” Though bottom line losses still dog the company, Abiomed slashed its net losses on a 16.8 percent top-line increase for the quarter.
The company reported net losses of $3.2 million, or 9 cents per diluted share, on sales of $23.4 million for the three months ended Sept. 30, its second-quarter, compared with net losses of $7.7 million, or 21 cents per diluted share, on sales of $20.0 million during the same period last year.
Termeer has been in headlines recently as Cambridge, Massachusetts-based Genzyme has dealt with a series of problems with its manufacturing facilities and resisted a takeover bid from French pharmaceuticals giant Sanofi-Aventis SA (NYSE:SNY). Rumors surfaced over the weekend that Japan’s Takeda Pharmaceuticals (TKO:4502) is in the running for the biotech giant.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
